Famotidine indications

List of indications
Duodenal ulcer Active benign gastric ulcer Gastroesophageal reflux disease Pathological hypersecretory conditions

Duodenal ulcer
Famotidine is indicated in short term treatment of active duodenal ulcer. Most adult patients heal within 4 weeks; there is rarely reason to use Famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of Famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. Famotidine is indicated in maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year. Return to top

Active benign gastric ulcer
Famotidine is indicated in short term treatment of active benign gastric ulcer. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of Famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. Return to top

Gastroesophageal reflux disease
Famotidine is indicated in short term treatment of gastroesophageal reflux disease (GERD). Famotidine is indicated for short term treatment of patients with symptoms of GERD. Famotidine is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy. Return to top

Pathological hypersecretory conditions
Famotidine is indicated in treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas). Return to top